

Product Data Sheet



Recombinant SARS-CoV-2 Envelope Protein

Product Code: 39504

Sengenics Corporation Pte Ltd

covid@sengenics.com

www.sengenics.com

Description:

Recombinant SARS-CoV-2 Envelope protein lysates, full length. Protein is expressed in baculovirus expression system in insect cells using the patented KREX™ functional proteomics technology.

Expression System:

Insect cell

GenBank Accession:

QHD43418.1

Synonym:

COVID-19, 2019-nCoV, SARS Coronavirus 2, E protein

Protein Length:

75aa

Expected Molecular Weight:

8.37kDa calculated from the sequence below

(https://www.bioinformatics.org/sms/prot_mw.html)

Form:

Liquid (Crude lysates)

Lysis Buffer:

25mM HEPES, 50mM KCl, 4mM CaCl₂, 20mM MgCl₂, 20% Glycerol, 0.2% Triton X-100, 0.2% BSA, 2mM DTT, 1 tablet Protease inhibitor (in 5mL buffer)

Storage Conditions:

-80° C, Avoid Freeze/Thaw Cycles

Stability:

Lysates are stable for up to 18 months from production date

Shipping:

Frozen shipment in dry ice

Authorised Uses:

For Research Use Only*

Applications:


Identification, development or production of a high-affinity vaccine; Development of an antigen-based COVID-19 sero-diagnostic test; Characterisation of full-length, correctly folded and functional SARS-CoV-2 antigens.

Sequence:

>SARS-CoV-2-EP

```
1 MYSFVSEETG TLIVNSVLLF LAFVVFLLVLT LAILTALRLC AYCCNIVNVS LVKPSFYVYS
61 RVKNLNSSRV PDLIV
```

Vector Map:



*All products and results from services are supplied handed over by us to you on the condition that they may only used by you alone (and no other third parties for and/or on your behalf) as instructed and directed in writing by Sengenics for your own internal, non commercial and non revenue and non fee generating research purposes only They are not in any circumstances to be used any other purposes, including but not limited to, for therapeutics or diagnostics, nor are they intended for use in or on humans By accepting delivery of our products or services, you are expressly agreeing to use our products or services for internal, non commercial and non revenue and non fee generating research purposes only as specified in this paragraph Products are not to be repackaged or resold and results from services are not to be use for any purpose apart from the research purposes specified in this paragraph.

Any non research use requires parties entering into a royalty bearing collaboration, services, commercial and/or license agreement The value of such license, royalties and/or revenue sharing is based upon the type of application of any Sengenics technologies, products or services for any purpose other than the internal, non commercial and non revenue and non fee generating research purposes specified in this paragraph.

**Sengenics technologies are protected by the following patents: JP4730804, GB2361698, US7816098, EP1470229, AU2003238441, US8999897, JP4377242, CA 2474457, EP1485411, CA2518927C, EP1456668, AU2002352355, JP4781628, US20180305840. Trademarked in the United Kingdom UK00003167383 under classes. 05, 10 and 16

Product Data Sheet



Recombinant SARS-CoV-2 Envelope Protein Product Code: 39504

Sengenics Corporation Pte Ltd
covid@sengenics.com
www.sengenics.com

Sequence alignment with reference sequence (QHD43418.1):

```
SARS-CoV-2-EP      MYSFVSEETGTLIVNSVLLFLAFVVFLLVTLAILTALRLCAYCCNIVNVLVKPSFYVYS 60  
QHD43418.1        MYSFVSEETGTLIVNSVLLFLAFVVFLLVTLAILTALRLCAYCCNIVNVLVKPSFYVYS 60  
*****
```

```
SARS-CoV-2-EP      RVKNLNSSRVPDLLV      75  
QHD43418.1        RVKNLNSSRVPDLLV      75  
*****
```

References:

1. Sengenics KREX™ proteomics technology [<https://www.sengenics.com/krex/>]
2. KREX™ is protected by multiple international patents worldwide [<https://www.sengenics.com/list-of-patents/>]
3. Blackburn, Jonathan M, and Aubrey Shoko. 2011. "Protein Function Microarrays for Customised Systems-Oriented Proteome Analysis." *Methods in molecular biology* (Clifton, N.J.) 785: 305–30
4. Beeton-Kempen, Natasha et al. 2014. "Development of a Novel, Quantitative Protein Microarray Platform for the Multiplexed Serological Analysis of Autoantibodies to Cancer-Testis Antigens." *International journal of cancer* 135(8): 1842–51
5. Other References [<https://www.sengenics.com/sengenics-krex-publications/>]

**All products and results from services are supplied handed over by us to you on the condition that they may only used by you alone (and no other third parties for and/or on your behalf) as instructed and directed in writing by Sengenics for your own internal, non commercial and non revenue and non fee generating research purposes only They are not in any circumstances to be used any other purposes, including but not limited to, for therapeutics or diagnostics, nor are they intended for use in or on humans By accepting delivery of our products or services, you are expressly agreeing to use our products or services for internal, non commercial and non revenue and non fee generating research purposes only as specified in this paragraph Products are not to be repackaged or resold and results from services are not to be use for any purpose apart from the research purposes specified in this paragraph.*

Any non research use requires parties entering into a royalty bearing collaboration, services, commercial and/or license agreement The value of such license, royalties and/or revenue sharing is based upon the type of application of any Sengenics technologies, products or services for any purpose other than the internal, non commercial and non revenue and non fee generating research purposes specified in this paragraph.

***Sengenics technologies are protected by the following patents: JP4730804, GB2361698, US7816098, EP1470229, AU2003238441, US8999897, JP4377242, CA 2474457, EP1485411, CA2518927C, EP1456668, AU2002352355, JP4781628, US20180305840. Trademarked in the United Kingdom UK00003167383 under classes. 05, 10 and 16*